AmoyDx Announces Companion Diagnostic Collaboration with AstraZeneca for PARP Inhibitor Lynparza in Ovarian Cancer

Amoy Diagnostics: Partnered with AstraZeneca for Companion Diagnostics of Targeted Drugs; the Company’s Self-Developed Human Homologous Recombination Deficiency (HRD) Test Product to Serve as Companion Diagnostic for AstraZeneca's PARP Inhibitor Lynparza (Olaparib) in Ovarian Cancer Indication in China, while Actively Promoting the Registration and Approval of the HRD Test Product with the National Medical Products Administration.